rs773516672
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PVS1PP3PP5_Very_Strong
The NM_000051.4(ATM):c.7449G>A(p.Trp2483*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000372 in 1,613,998 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000051.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.7449G>A | p.Trp2483* | stop_gained | Exon 50 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152150Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251260Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135782
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461848Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 2AN XY: 727224
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152150Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74330
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Pathogenic:2
Variant summary: ATM c.7449G>A (p.Trp2483X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 1.6e-05 in 251260 control chromosomes. c.7449G>A has been reported in the literature in individuals affected with Ataxia-Telangiectasia (example, Telatar_1998, Eng_2004). These data indicate that the variant is likely to be associated with disease. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
This sequence change creates a premature translational stop signal (p.Trp2483*) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is present in population databases (rs773516672, gnomAD 0.009%). This premature translational stop signal has been observed in individual(s) with ataxia-telangiectasia (PMID: 9443866, 9682216). ClinVar contains an entry for this variant (Variation ID: 245972). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Familial cancer of breast Pathogenic:2
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
- -
Hereditary cancer-predisposing syndrome Pathogenic:2
This variant changes 1 nucleotide in exon 50 of the ATM gene, creating a premature translation stop signal. In addition, this variant creates a new splice site which results in the deletion of the last 70 nucleotides of exon 50 (also described as exon 52 in the literature)(PMID: 9682216, 14695534). This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with ataxia telangiectasia and is considered a founder mutation in the Costa Rican population (PMID: 9682216, 14695534). This variant has also been reported in a Turkish individual affected with breast cancer (DOI: 10.7197/cmj.vi.623656). This variant has been identified in 4/251260 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
The p.W2483* pathogenic mutation (also known as c.7449G>A), located in coding exon 49 of the ATM gene, results from a G to A substitution at nucleotide position 7449. This changes the amino acid from a tryptophan to a stop codon within coding exon 49. This mutation has been reported in multiple Costa Rican individuals with ataxia telangiectasia, suggesting a founder effect in this population (Telatar M et al. Mol. Genet. Metab. 1998 May; 64(1):36-43; Telatar M et al. Am. J. Hum. Genet. 1998 Jan; 62(1):86-97). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
not provided Pathogenic:1
This pathogenic variant is denoted ATM c.7449G>A at the cDNA level and p.Trp2483Ter (W2483X) at the protein level. The substitution creates a nonsense variant, which changes a Tryptophan to a premature stop codon (TGG>TGA) ; however, Eng et al. (2004) have also demonstrated that this variant creates a cryptic splice donor site resulting in a deletion of the last 70 nucleotides of exon 50, previously referred to as exon 52. Consistent with these results, multiple splicing models predict that this variant leads to the creation of a strong cryptic splice donor site. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. ATM c.7449G>A has been reported in multiple patients with Ataxia-telangiectasia and is suggested to be a founder mutation in the Costa Rican population (Telatar 1998, Eng 2004). We consider it to be pathogenic.The ATM protein is a member of the phosphatidylinositol 3-kinase family of proteins that respond to DNA damage by phosphorylating key substrates involved in DNA repair and/or cell cycle control (MIM:607585). Homozygous or compound heterozygous pathogenic variants in the ATM gene are associated with Ataxia-telangiectasia (A-T), an autosomal recessive multisystem disorder characterized by progressive neurodegeneration, telangiectasias, immunodeficiency and increased risk of cancers, particularly for leukemia and lymphoma (MIM:208900, Gatti 2010). Individuals with A-T are also unusually sensitive to ionizing radiation (Gatti 2010). Although symptom onset for A-T typically occurs in childhood, milder adult-onset variant forms of A-T have been reported in individuals with identified homozygous or compound heterozygous pathogenic variants in ATM (McConville 1996, Verhagen 2009, Saunders-Pullman 2012). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at